pharmaphorum

NOVEMBER 6, 2020

Its lead candidate in clinical development is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is being tested in a phase 1 and a phase 2 clinical trial for patients with blood cancer and solid tumours, respectively. The transaction is expected to close at the end of 2020.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

pharmaphorum

JULY 14, 2022

In a statement , the health technology assessment (HTA) organisation said that the two drugs were backed after an agreement with the two developers on pricing that will make them an option for around 3,450 NHS patients.

Drugs 104

Drugs Hormones Genomics Genome 104

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Trop-2 is highly expressed across multiple cancer types, with expression detected in more than 90% of breast cancers.

HR 162

HR Marketing Hormones FDA Approval 162

Pharmaceutical Technology

FEBRUARY 18, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The drug candidate is administered orally.

Hormones 100

Hormones Development Production Clinical Trials 100

XTalks

DECEMBER 5, 2024

Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

pharmaphorum

FEBRUARY 21, 2022

” The antibody-drug conjugate is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the DESTINY-Breast03 study looks set to expand its use into second-line treatment in breast cancer. AZ paid a hefty $1.4

Trials 132

Trials Sales Hormones Drugs 132

XTalks

DECEMBER 5, 2024

Amgen’s randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of ≥30 or ≥27, respectively, with at least one obesity-related comorbidity. “We

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 5, 2024

SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Septerna’s thyroid-stimulating hormone receptor (TSHR) modulators offer a potentially disease-modifying oral treatment. Phase I trials are underway, with data expected in mid-2025. million patients in the US.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

MARCH 29, 2021

Grantz, of the Division of Intramural Population Health Research at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. Katherine L.

Genotype 98

Genotype Allergies Hormones Research 98

pharmaphorum

JULY 13, 2022

Merck – known as MSD outside the US and Canada – is paying $290 million upfront for global co-development and co-marketing rights to ODM-208, a steroid synthesis inhibitor, as well as follow-up compounds in the same class. Further financial terms have not been disclosed.

Licensing 52

Licensing Licensing Hormones Production 52

The Pharma Data

JUNE 26, 2021

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis. Harnessing the power of antibodies to fight bone metastasis. “We feel our strategy is a real game changer.”

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 7, 2021

Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some of the assets that will be key revenue drives for the company. That’s a significant goal.

Protein 52

Protein Antibody Genetics Gene Therapy 52

XTalks

SEPTEMBER 17, 2020

While the table lists acceptable surrogate endpoints for trials of more common conditions, such as asthma, type 2 diabetes and various cancer types, the document also provides key information to developers of certain rare disease therapies. The tumor secretes adrenocorticotropic hormone (ACTH), which stimulates cortisol production.

Trials 98

Trials Gene Hormones Clinical Trials 98

Roots Analysis

OCTOBER 24, 2023

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. Different Types of HPAPIs The new generation of APIs being developed are highly complex in nature, including peptides, HPAPIs, oligonucleotides and sterile APIs.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

pharmaphorum

JANUARY 10, 2023

It was approved by the FDA as Sotyktu last September; 5) Foscarbidopa/foslevodopa ( ABBV-951 ): Developed by AbbVie, the drug is a reformulation of a standard Parkinson’s treatment (carbidopa/levodopa) delivered by subcutaneous pump for hard-to-treat patients with advanced disease, and is in the latter stages of FDA review.

Drugs 52

Drugs Gene Therapy Antibody Insulin 52

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52

The Pharma Data

DECEMBER 27, 2020

ASC42 is an in-house developed?novel The oral tablet formulation of ASC42 has been developed with the in-house proprietary technology and is stable at room temperature. “Combining ASC42 with ASC40, a fatty acid synthase (FASN) inhibitor or ASC41, a thyroid hormone receptor beta (THR-?) . ” About Ascletis.

Trials 40

Trials Hormones Development Drugs 40

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. Alexion’s new development hub.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. GSK’s Benlysta (belimumab) is a monoclonal antibody that was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of SLE.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

Roots Analysis

MAY 21, 2024

Extensive research on the role of protein homeostasis in these disease conditions has paved the way for development of the small molecules that can target various components of UPS to enable efficient degradation of proteins. This limitation has paved the way for the development of targeted protein degradation approaches.

Protein 40

Protein Marketing Development Antibody 40

XTalks

MARCH 8, 2024

Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK. Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.

Drugs 59

Drugs FDA Approval Production Immune Response 59

The Pharma Data

AUGUST 6, 2020

Roche’s Chief Medical Officer and Head of Global Product Development. Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across several types of lung, genitourinary, skin, breast, gastrointestinal, gynaecological and head and neck cancers.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR 52

HR Medicine In-Vitro Development 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Monoclonal antibodies (mAbs). Blood and blood components. Allergenics. Somatic cells. Gene and cellular therapies.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

SEPTEMBER 28, 2022

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted four new approvals for Merck ’s (MSD outside North America) humanised monoclonal antibody, Keytruda (pembrolizumab), to treat various types of cancers. With the latest development, the antibody is indicated for 23 usages in 13 different cancer types of cancer in the country.

Antibody 147

Antibody Clinical Trials Clinical Trials Hormones 147

Camargo

AUGUST 18, 2021

Development and Reproductive Toxicology studies, or DART studies, are required for most non-oncology programs between IND and NDA filings. Fertility and embryonic development. Late embryogenesis, early fetal development including major organ formation. Timing of DART Studies. Rodent (rat or mouse, both sexes). Segment II.

Clinical Trials 243

Clinical Trials Clinical Trials Development Hormones 243

XTalks

FEBRUARY 5, 2024

This article serves as a resource for healthcare professionals, life sciences researchers and industry enthusiasts seeking to stay informed of the latest developments and success stories in oncology therapeutics. Darzalex (Daratumumab) Darzalex 2022 Sales: $7.977 billion Company/Developer: Janssen Biotech, Inc.,

FDA Approval 101

FDA Approval Drugs Sales Development 101

pharmaphorum

DECEMBER 23, 2020

Originally developed to treat late-stage EGFR-mutated disease, the ADAURA study tested Tagrisso as an adjuvant treatment in patients with early disease following surgery. A molecule codenamed DNL151, currently in phase 1 development, has been selected to progress into late-stage clinical studies that are expected to begin in 2021.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

pharmaphorum

DECEMBER 12, 2022

Along with data from its antibody-drug conjugates and oral selective oestrogen receptor degrader (SERD) camizestrant reported earlier, AZ presented results of the CAPItello trial of AKT inhibitor capivasertib in combination with injectable SERD Faslodex (fulvestrant) in hormone receptor positive, HER2-negative advanced breast cancer.

HR 105

HR Hormones Trials Drugs 105

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Licensing 130

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. NGM120 is a first-in-class antagonistic antibody, which binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15).

Marketing 94

Marketing Pharma Companies Development Hormones 94

XTalks

MARCH 22, 2021

And as big pharma works on developing and growing their oncology portfolios, the rising trend of such mergers and acquisitions won’t be slowing down any time soon. Resolution has been a leader in the development of NGS-based companion diagnostics (CDx) test development and registration services for precision oncology.

Life Science 110

Life Science Development Marketing Gene Expression 110

pharmaphorum

JULY 8, 2021

million grant will be used to develop a new class of small-molecule inhibitors of M pro , a protease enzyme essential for the replication of the SARS-CoV-2 virus. The latest Gates Foundation grant comes on top of earlier awards for tuberculosis, malaria and non-hormonal contraceptives which were announced earlier this year.

Drugs 111

Drugs Hormones Medicine Antibody 111